ProMIS Neurosciences Inc. filings document a clinical-stage biotechnology issuer with common shares listed on the Nasdaq Capital Market and organized in Ontario, Canada. Formal disclosures cover PMN310 and related clinical or regulatory updates, operating results, financing arrangements, registered security status, and the company’s capital structure, including common shares, purchase warrants, pre-funded warrants, and share consolidation actions.
Proxy and 8-K filings record shareholder voting matters, director elections, independent auditor ratification, equity incentive plan proposals, board appointments, and other governance changes. The filing record also documents Nasdaq listing compliance matters, material definitive agreements, and financial condition disclosures connected to the company’s neurodegenerative-disease development programs.
ProMIS Neurosciences Inc. director Madge K. Shafmaster reported two option awards that provide the right to buy common shares. One grant covers 11,000 underlying common shares at an exercise price of $10.7700 per share and expires on May 20, 2036.
According to the filing, another grant covers 5,500 underlying common shares at the same $10.7700 exercise price and the same expiration date. One option vests in full on May 20, 2027, while the other vests 25% at grant with the remaining shares vesting ratably over thirty-six months, in each case subject to continued service on the Board.
ProMIS Neurosciences Inc. reported that Chief Scientific Officer Neil Cashman received a grant of options to buy 50,000 Common Shares. These options have an exercise price of $10.77 per share and expire on May 20, 2036. The award was made at no cost to him and represents equity-based compensation rather than an open-market purchase or sale. According to a footnote, the options vest ratably over four years, contingent on his continued service with the company. Following this grant, he holds 50,000 options directly.
ProMIS Neurosciences Inc. reported that its Principal Accounting Officer, Max A. Milbury, received a compensation-related grant of stock options. The award covers 18,167 options to buy Common Shares at an exercise price of $10.77 per share, expiring on May 20, 2036. These options were granted at no cost and increase his directly held option position to 18,167 derivative securities. According to the disclosure, the options will vest ratably over four years, conditioned on his continued service with the company.
ProMIS Neurosciences Inc. reported that director Josh Mandel-Brehm received two option grants covering a total of 16,500 options to buy Common Shares. One grant covers 11,000 options at an exercise price of $10.77 per share, vesting in full on May 20, 2027, subject to continued Board service. The second grant covers 5,500 options at the same $10.77 exercise price, with 25% vesting immediately on grant and the remaining shares vesting ratably over 36 months, also tied to continued Board service. Both option awards expire on May 20, 2036, and represent compensation-related acquisitions rather than open-market purchases or sales.
ProMIS Neurosciences Inc. reported that Chief Development Officer Johanne Kaplan received a grant of options to acquire 50,000 Common Shares. The options have an exercise price of $10.77 per share and expire on May 20, 2036.
The award was granted at no cost and vests ratably over four years, subject to her continued service with the company. This filing reflects routine equity compensation and does not involve any open-market purchases or sales of the company’s shares.
ProMIS Neurosciences Inc. director Alex Slanix Paul reported receiving two grants of stock options. One award covers 11,000 options to buy Common Shares at an exercise price of $10.77 per share, expiring on May 20, 2036, that vest in full on May 20, 2027 subject to continued Board service. A second award covers 5,500 options at the same exercise price and expiration date, with 25% vesting immediately on grant and the remaining options vesting ratably over thirty-six months, also contingent on continued service.
ProMIS Neurosciences Inc. reported results of its 2026 annual meeting, where shareholders approved an amendment to the 2025 Stock Option and Incentive Plan to increase the shares available for issuance by 900,000 Common Shares. Seven director nominees were elected, each receiving more than 4.1 million votes for, with broker non-votes of 614,643.
Shareholder participation was moderate, with 4,762,024 Common Shares, or about 53.1% of the 8,967,693 shares outstanding as of the record date, present or represented by proxy. Shareholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
PROMIS Neurosciences Inc. ownership disclosure: Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl report shared beneficial ownership of 954,082 common shares, representing 9.99% of the class based on 9,550,373 shares outstanding.
The filing explains that the 9,550,373 base includes 8,967,693 common shares outstanding as reported by the issuer and 582,680 shares exercisable from warrants held by the reporting persons, limited by a Beneficial Ownership Cap that prevents exercise beyond 9.99%. Great Point states it is investment manager to related funds (BVF and BOVF) and the Reporting Persons disclaim beneficial ownership of those fund shares except to the extent of pecuniary interest. The Reporting Persons executed a Joint Filing Agreement dated May 15, 2026.
ProMIS Neurosciences (PMN) Schedule 13G: Wellington Management Group LLP reports beneficial ownership of 895,871 shares of ProMIS common stock, representing 9.99% of the class. The position consists of 696,378 shares held directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P. and 199,493 shares issuable upon exercise of warrants. The filers state an exercise limitation excludes 496,885 warrant shares from beneficial ownership calculations to enforce a 9.99% ownership cap. The ownership percentage is calculated using 8,967,693 shares outstanding as of March 25, 2026 per the company’s 10-K.
ProMIS Neurosciences Inc. reported a Q1 2026 net loss of $8.2 million, or $1.26 per share, compared with a $7.3 million loss a year earlier, as it ramped investment in its Alzheimer’s program PMN310. Research and development expenses rose to $7.0 million, including $6.3 million for PMN310, while general and administrative costs declined to $1.7 million.
In January 2026 the company strengthened its balance sheet with $70.1 million of net proceeds from a private placement of common shares, pre-funded warrants, and common share warrants, lifting cash to $63.8 million and total assets to $67.4 million as of March 31, 2026. Management now expects existing cash and short-term investments to fund operations through 2027.
The Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer’s disease has enrolled 144 patients across 21 U.S. sites. The study, which has FDA Fast Track designation, is designed to assess safety, amyloid-related imaging abnormalities, biomarkers, and early clinical outcomes, with a blinded interim analysis anticipated in early third quarter 2026 and top-line data expected in early 2027.